Trump’s 100% tariffs on branded drugs: Indian generics spared but poses risks for pharma sector – Explained
US President Trump announced a 100% tariff on imported branded and patented pharmaceuticals starting October 2025, aiming to boost domestic manufacturing. Indian generic drug makers ...
Trump’s 100% pharma tariffs: How bad will India’s pharmaceutical exports be hit? L’ow-cost generic model may offer cushion’
Donald Trump announced 100% tariffs on imported branded or patented pharmaceutical products from October 1, 2025, unless companies build US manufacturing facilities. This policy primarily ...
Trump’s 100% tariffs on pharma: Sun Pharma, Biocon, Cipla & other pharmaceutical stocks tank; jitters on D-Street
Pharmaceutical stocks, particularly Indian firms, plummeted following President Trump’s announcement of 100% tariffs on imported branded medicines to the US. Companies like Sun Pharma, Biocon, ...
Pharma sector outlook: ICRA pegs 7-9% revenue growth for FY26, US headwinds cloud prospects
India’s pharmaceutical sector is poised for strong revenue growth, projecting 7-9% in FY26, driven by domestic and European demand. While US market growth may moderate, ...
`Indian pharma resilient to potential US tariffs’
India Ratings and Research (Ind-Ra) anticipates minimal credit profile impact on Indian pharma companies from potential US tariffs on pharmaceutical imports. While the US accounts ...
